- Home
- LOGC vs MOLN Comparison
LOGC vs MOLN Comparison
Compare LOGC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- MOLN
- Stock Information
- Founded
- LOGC 2010
- MOLN 2004
- Country
- LOGC United States
- MOLN Switzerland
- Employees
- LOGC N/A
- MOLN N/A
- Industry
- LOGC Catalog/Specialty Distribution
- MOLN
- Sector
- LOGC Consumer Discretionary
- MOLN
- Exchange
- LOGC Nasdaq
- MOLN Nasdaq
- Market Cap
- LOGC 174.3M
- MOLN 195.4M
- IPO Year
- LOGC 2020
- MOLN 2021
- Fundamental
- Price
- LOGC $6.46
- MOLN $5.38
- Analyst Decision
- LOGC
- MOLN
- Analyst Count
- LOGC 0
- MOLN 0
- Target Price
- LOGC N/A
- MOLN N/A
- AVG Volume (30 Days)
- LOGC 206.9K
- MOLN 7.6K
- Earning Date
- LOGC 03-03-2025
- MOLN 08-26-2024
- Dividend Yield
- LOGC N/A
- MOLN N/A
- EPS Growth
- LOGC N/A
- MOLN N/A
- EPS
- LOGC N/A
- MOLN N/A
- Revenue
- LOGC $96,000,000.00
- MOLN $7,105,397.00
- Revenue This Year
- LOGC N/A
- MOLN N/A
- Revenue Next Year
- LOGC $422.91
- MOLN $29.41
- P/E Ratio
- LOGC N/A
- MOLN N/A
- Revenue Growth
- LOGC N/A
- MOLN N/A
- 52 Week Low
- LOGC $4.01
- MOLN $3.32
- 52 Week High
- LOGC $8.24
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- LOGC 37.74
- MOLN 51.62
- Support Level
- LOGC $6.52
- MOLN $4.98
- Resistance Level
- LOGC $7.42
- MOLN $5.50
- Average True Range (ATR)
- LOGC 0.32
- MOLN 0.20
- MACD
- LOGC -0.06
- MOLN 0.04
- Stochastic Oscillator
- LOGC 15.11
- MOLN 84.04
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.